First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC

被引：0
|
作者：
Wang, Lijie
Gao, Ming
Yang, Wenyu
Wang, Chunyu
Wang, Ting
Jing, Fangfang
Ma, Junxun
Zhang, Fan
Tao, Haitao
Hu, Yi
机构：
[1] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Med Oncol, Beijing, Peoples R China
[3] Nankai Univ, Sch Med, Tianjin, Peoples R China
[4] Peoples Liberat Army Gen Hosp, Med Ctr 1, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol 5, Beijing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21100
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Feng, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
  • [2] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Du, X.
    Feng, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318
  • [3] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
    Lu, S.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    Zhuang, W.
    Liu, Y.
    Li, W.
    Cui, J.
    Wang, D.
    Liao, W.
    Wang, M.
    Zhou, J.
    Wang, Z.
    Sun, Y.
    Gao, J.
    Bao, Y.
    Liang, L.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
  • [4] Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
    Zhao, J.
    Wang, Z.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Li, J.
    Xia, F.
    Wang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S540 - S540
  • [5] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
  • [6] RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.
    Wang, Jie
    Lu, Shun
    Yu, Xinmin
    Hu, Yanping
    Sun, Yuping
    Wang, Zhijie
    Zhao, Jun
    Yu, Yan
    Hu, Chunhong
    Yang, Kunyu
    Feng, Guosheng
    Ying, Kejing
    Zhuang, Wu
    Zhou, Jianying
    Wu, Jingxun
    Leaw, Shiang Jiin
    Zhang, Jing
    Lin, Xiao
    Yang, Nong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
    Wang, Z.
    Zhao, J.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Wu, Y.
    Ma, Y.
    Tan, W.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444
  • [8] First-Line Nivolumab Plus Ipilimumab versus Chemotherapy in NSCLC
    不详
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 465 - 465
  • [9] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [10] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
12345